FIELD: chemistry.
SUBSTANCE: present invention is applied to compounds of formula I, in which R1 represents a group having the formula given below, and other groups and symbols have values given in the claim, separate specific compounds and pharmaceutical compositions containing them.
,
R1.
EFFECT: declared compounds are apelin (APJ) receptor agonists and can be used for treating a condition or disorder associated with an apelin receptor agonist, such as, for example, asthma, cardiomyopathy, diabetes, dyslipidemia, hypertension, inflammation, liver disease, metabolic disorders, neurodegenerative diseases, obesity, preeclampsia or renal insufficiency.
29 cl, 1 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED APELIN RECEPTOR AGONISTS (APJ) AND THEIR USE | 2016 |
|
RU2766148C1 |
| FGFR INHIBITOR AND ITS APPLICATION | 2018 |
|
RU2745035C1 |
| HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL AGENT BASED ON THEREOF AND METHOD OF TREATMENT | 2002 |
|
RU2299197C2 |
| INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF | 2015 |
|
RU2719428C2 |
| FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | 2014 |
|
RU2704112C2 |
| 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | 2013 |
|
RU2576384C1 |
| DERIVATIVES OF BENZISOXAZOLESULFONAMIDE | 2020 |
|
RU2813356C2 |
| CONDENSED HETEROCYCLIC COMPOUND | 2005 |
|
RU2389731C2 |
| INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
| ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | 2014 |
|
RU2664118C2 |
